Race Oncology (ASX: RAC) – The ASX Biotech With A Global Opportunity To Change Cancer Treatment

TL;DR

Race Oncology is a precision oncology company developing a drug called Byzantran that targets a wide range of cancers, with significant developments in clinical trials and preclinical research.

Transcript

hey guys and welcome back to the asx investor channel welcome back to another asx interview today we are very excited to be revisiting the race oncology story asx rac are an exciting company playing in the precision oncology space they've got an incredible drug by santrine which has over the past year had a very transformative period there's been a... Read More

Key Insights

• 🧡 Byzantran has shown potential in targeting a wide range of cancers driven by the protein FTO.
• 🧑‍✈️ Clinical trials for AML are progressing well, with promising results from a pilot study and the potential for a cost-effective pathway to approval.
• 👨‍🔬 Preclinical research is underway to explore additional applications for Byzantran, including clear cell renal cell carcinoma, extra-medullary AML, and its potential to overcome resistance to checkpoint inhibitors.
• 🐎 Race Oncology aims to attract partnerships or acquisitions with larger pharmaceutical companies to further develop and commercialize Byzantran.
• 🤨 The company strives to maintain strong communication and transparency with its shareholders, rewarding them through friendly capital raises and active engagement.
• 👀 Over the next 12 to 18 months, investors should watch for clinical data readouts, preclinical updates, and potential partnerships or acquisitions that could drive the commercialization of Byzantran.

Questions & Answers

Q: What is the main focus of Race Oncology?

Race Oncology is focused on developing Byzantran, a precision oncology drug that targets the protein FTO involved in regulating RNA and the development of various cancers.

Q: How many cancers are known to be driven by FTO?

Currently, 22 different types of cancers have been identified as being driven by FTO, including lung, breast, brain, pancreatic, and leukemias.

Q: What are the three pillars of Race Oncology's strategy?

The three pillars are FTO-driven cancers, breast cancer, and acute myeloid leukemia (AML). Each pillar represents a significant opportunity for development and impact.

Q: What are the ongoing clinical trials for AML being conducted by Race Oncology?

Race Oncology is conducting two trials for AML, one in collaboration with investigators in Israel and another in Australia. The trials involve using Byzantran in combination with other drugs to target AML, including extra-medullary AML.

Summary & Key Takeaways

• Race Oncology is developing Byzantran, a drug targeting a protein called FTO that plays a crucial role in the development and spread of various types of cancers.

• The company has implemented a three-pillar strategy, focusing on FTO-driven cancers, breast cancer, and acute myeloid leukemia (AML).

• Clinical trials for AML are underway in Australia and Israel, with promising results in a pilot study and plans for a larger trial. A two-part trial for AML patients with extra-medullary disease is also being conducted in Australia.